IP Library Granted Patent US 9,005,954
Granted Patent B2
US 9,005,954 · App. 13/145,246 · Granted Apr 14, 2015

Methods for isolating bacteria

Inventors: Jean-Paul Leonetti (Castelnau le Lez, FR); Stéphanie Texier (Montpellier, FR)
Assignees: Deinove; Centre National de la Recherche Scientifique
C12N13/00C12N1/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,954
App. No.
13/145,246
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention relates to compositions and methods to identify novel bacteria and metabolites derived therefrom. More specifically, the invention describes a novel method to isolate bacteria producing metabolites of interest from environmental samples. Particularly, the invention discloses a method to select rare antibiotic producing bacteria. The invention can be used from any sample and allows the isolation of bacteria having e.g., pharmaceutical or agrochemical interest.

Claims (24)

1. A method to identify or isolate from a sample a bacterium producing a pharmaceutical compound, the method comprising:

a) providing a sample comprising uncharacterized and uncultivated bacteria;

b) subjecting the sample to a repeated sequential irradiation treatment that is sufficient to reduce by at least 2 log the bacterial titer in a culture of E. coli , said treatment comprising at least 2 sequential irradiations at intervals of between 1 and 8 hours;

c) identifying or isolating a living or growing bacterium having the ability to either reassemble its genome or to resist DNA damage, from said treated sample; and

d) selecting a bacterium of step e) which produces the pharmaceutical compound.

2. The method of claim 1 , wherein the sample is an environmental sample.

3. The method of claim 1 , wherein said treatment comprises repeated irradiations selected from UV-, gamma- and/or X ray-irradiation(s), either alone or in combination.

4. The method of claim 1 , wherein the treatment comprises subjecting the sample to 2 to 5 UV treatments of between 0.5 and 400 mJ/cm 2 carried out at an interval of between 1 and 8 hours.

5. The method of claim 1 , further comprising a step of selecting a Deinococcus bacterium.

6. The method of claim 1 , wherein step b) is performed in a solid culture medium.

7. The method of claim 1 , wherein, in step c), colonies are identified or isolated.

8. The method of claim 1 , wherein steps c) and d) are performed sequentially, in any order, or simultaneously.

9. The method of claim 1 , wherein step d) comprises exposing identified or isolated bacteria of step c) to one or several indicator cells and selecting a bacterium which affects the viability, growth, metabolism, mobility, RNA expression, protein expression, protein secretion or virus production of at least one of said indicator cells.

10. The method of claim 1 , wherein the method comprises a further step of isolating or purifying said pharmaceutical compound.

11. A method of producing a pharmaceutical compound selected from an antibiotic or bacteriostatic or anti-fungal or anti-parasitic or anti-viral or anti-metabolite or chemotherapeutic agent or a cytokine-activity compound or cell growth factor, the method comprising identifying or isolating a pharmaceutical compound-producing bacterium according to the method of claim 1 and producing said pharmaceutical compound.

12. A method of producing a recombinant host cell, the method comprising identifying or isolating a bacterium according to the method of claim 1 , and cloning one or several genes from said bacterium in another host cell to produce a recombinant host cell.

13. The method of claim 1 , wherein the repeated sequential irradiation treatment comprises three UV treatments of 4 mJ/cm 2 carried out at an interval of 4 hours.

14. The method of claim 1 , wherein the pharmaceutical compound is selected from antibiotics, bacteriostatic compounds, anti-metabolite, chemotherapeutic compounds, anti-parasitic agents, anti-fungal agents, anti-viral compounds, cytokine-activity compounds or cell-growth factors.

15. The method of claim 14 , wherein said pharmaceutical compound is an antibiotic.

16. The method of claim 15 , wherein said antibiotic inhibits the growth of Staphylococcus aureus.

17. The method of claim 15 , wherein said antibiotic inhibits the growth of Candida tropicalis.

18. The method of claim 15 , wherein said antibiotic inhibits the growth of Escherichia coli.

19. The method of claim 15 , wherein said antibiotic inhibits the growth of Streptococcus pneumoniae.

20. The method of claim 15 , wherein said antibiotic inhibits the growth of Pseudomonas aeruginosa.

Assignments (3)
CHANGE OF NAME Recorded Feb 17, 2016
From: UNIVERSITÉ MONTPELLIER 1
To: UNIVERSITÉ DE MONTPELLIER
Reel/Frame 037748/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2016
From: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
To: UNIVERSITÉ MONTPELLIER 1
Reel/Frame 037734/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2011
From: LEONETTI, JEAN-PAUL; TEXIER, STEPHANIE
To: DEINOVE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 026748/0432 →
Priority Claims (1)
EP 09305041 · Jan 19, 2009 · regional
Continuity (2)
Provisional Application 61145606 · Jan 19, 2009
Related Publication 20110294979A1 · Dec 1, 2011